
Significant reduction in 6-year fragility fracture risk with zoledronate vs placebo for osteopenia
How to Cite
OrthoEvidence. Significant reduction in 6-year fragility fracture risk with zoledronate vs placebo for osteopenia. ACE Report. 2019;8(4):17. Available from: https://myorthoevidene.com/AceReport/Report/11001
Fracture Prevention with Zoledronate in Older Women with Osteopenia
N Engl J Med. 2018 Dec 20;379(25):2407-2416. doi: 10.1056/NEJMoa1808082Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
2000 postmenopausal women with osteopenia were randomized to treatment with infusion of either zoledronate 5mg or placebo every 18 months for 6 years. Participants were assessed for incidence of fractures, prespecified adverse events including mortality, vascular events, cancer, and osteonecrosis of the jaw, and bone mineral density after 6 years. Results demonstrated significantly lower incidence...
To view the full report, start your 30-day free trial today
No credit card required
JOIN LOGIN Forgot Password?Not sure if you want to join OrthoEvidence?
Access this report without an Account.Success, an email containing a link to access this report has been sent to your inbox.
Explore some of our unlocked reports below!

Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.
LEARN MORE
Please Login or Join to leave comments.